Pharmacy delivery service PillSorted dispensed £4.7m in seed funding

pillsorted seed funding

Pharmacy delivery service PillSorted has raised $6m (£4.7m) in seed funding.

Founded in 2019 by pharmacist Zeinab Ardeshir and Mohammad Mohaghegh, PillSorted will use the capital injection for product development, growing its service in London and across the rest of the UK.

A new trial will see the service extended to supporting care workers.

London-based PillSorted is a personalised medication home delivery service. Its team of data scientists use algorithms that aim to give better advice and improve results, reducing the cost of medication.

For pharmacists, PillSorted uses automation to remove the admin associated with manually processing prescriptions. Its operating system allows pharmacists to turn conversations into consultations and offer GP referrals. PillSorted also taps into the NHS through connections, including NHS Spine.

“The typical pharmacy experience has long been in need of an upgrade, and most pharmacists, despite being well trained and highly knowledgeable, are so bogged down by manual, repetitive tasks that they only have time to provide a basic, transactional service,” said Zeinab Ardeshir, CEO and co-founder, PillSorted.

Patients using PillSorted can request digital consultations with a pharmacist whenever they want. PillSorted delivery is managed by its own fleet, which allows it to guarantee delivery before medication runs out and provide critical medication when required.

“Our mission is to provide a personalised pharmacy service for people who are on lots of medication that makes accessing the drugs and support they need a whole lot easier for them,” added Ardeshir.

Investment came from Pear VC, Hoxton Ventures, Edison and the founders of DoorDash.

“PillSorted leverages technology to fulfil and deliver pharmacy products while creating personalised and human-focused experiences. It’s the blueprint for a future in which patients are consistently able to get the medicines they need at home before they need them,” said Pepe Agell, partner, Pear VC.

Medtech Epitopea this week raised £10.3m in seed funding to continue its research into tumour specific antigens.